Folate-Cyclodextrin Conjugate for Targeted Chemotherapy

    March 2021 in “ Arrow - TU Dublin (Technological University Dublin) ”
    Zlata Tofzikovskaya, Orla Howe, Mary McNamara, Christine O’Connor
    TLDR The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.
    The study explored the development of a folate-cyclodextrin conjugate (CDEnFA) as a targeted drug delivery system for chemotherapy, aiming to reduce side effects like hair loss by specifically targeting cancer cells. The conjugate was tested for cytotoxicity on folate over-expressing HeLa cells and folate receptor-deficient A549 cells, with EC50 values compared to the standard chemotherapy drug, Cisplatin. This approach aimed to improve the selectivity of anticancer drugs, potentially minimizing damage to healthy cells.
    Discuss this study in the Community →